View in EDS

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.

Saved in:
Bibliographic Details
Title: Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Authors: Xu C; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts. Chunxiao.xu@emdserono.com yan.lan@emdserono.com., Zhang Y; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Rolfe PA; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Hernández VM; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Guzman W; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Kradjian G; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Marelli B; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Qin G; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Qi J; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Wang H; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Yu H; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Tighe R; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Lo KM; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., English JM; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Radvanyi L; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts., Lan Y; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts. Chunxiao.xu@emdserono.com yan.lan@emdserono.com.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Oct 01; Vol. 23 (19), pp. 5869-5880. Date of Electronic Publication: 2017 Jul 05.
Publication Type: Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 28679778
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Xu+C%22">Xu C</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts. Chunxiao.xu@emdserono.com yan.lan@emdserono.com.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Rolfe+PA%22">Rolfe PA</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Hernández+VM%22">Hernández VM</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Guzman+W%22">Guzman W</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Kradjian+G%22">Kradjian G</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Marelli+B%22">Marelli B</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Qin+G%22">Qin G</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Qi+J%22">Qi J</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Yu+H%22">Yu H</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Tighe+R%22">Tighe R</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Lo+KM%22">Lo KM</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22English+JM%22">English JM</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Radvanyi+L%22">Radvanyi L</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Lan+Y%22">Lan Y</searchLink>; Immuno-Oncology Translational Innovation Platform, EMD Serono Research and Development Institute, Billerica, Massachusetts. Chunxiao.xu@emdserono.com yan.lan@emdserono.com.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2017 Oct 01; Vol. 23 (19), pp. 5869-5880. <i>Date of Electronic Publication: </i>2017 Jul 05.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28679778
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-17-0483
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5869
    Titles:
      – TitleFull: Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Xu C
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Rolfe PA
      – PersonEntity:
          Name:
            NameFull: Hernández VM
      – PersonEntity:
          Name:
            NameFull: Guzman W
      – PersonEntity:
          Name:
            NameFull: Kradjian G
      – PersonEntity:
          Name:
            NameFull: Marelli B
      – PersonEntity:
          Name:
            NameFull: Qin G
      – PersonEntity:
          Name:
            NameFull: Qi J
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Yu H
      – PersonEntity:
          Name:
            NameFull: Tighe R
      – PersonEntity:
          Name:
            NameFull: Lo KM
      – PersonEntity:
          Name:
            NameFull: English JM
      – PersonEntity:
          Name:
            NameFull: Radvanyi L
      – PersonEntity:
          Name:
            NameFull: Lan Y
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2017 Oct 01
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 19
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1